Last reviewed · How we verify
Placebo of Nifedipine
Placebo of Nifedipine is a calcium channel blocker Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Hypertension, Angina pectoris.
Nifedipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.
Nifedipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Placebo of Nifedipine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | calcium channel blocker |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of calcium ions into smooth muscle cells, leading to vasodilation and a subsequent decrease in blood pressure. This mechanism is particularly effective in treating hypertension and angina pectoris.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Edema
- Headache
- Dizziness
Key clinical trials
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation (PHASE3)
- Sitaxsentan in Proteinuric Chronic Kidney Disease (PHASE2)
- Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema (NA)
- Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor (PHASE4)
- Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects (PHASE2)
- Medicine-induced Cardiac Hemodialysis on COVID-19 (PHASE4)
- Three New Ideas to Protect Special Forces From the Stress of High Altitude (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Nifedipine CI brief — competitive landscape report
- Placebo of Nifedipine updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Placebo of Nifedipine
What is Placebo of Nifedipine?
How does Placebo of Nifedipine work?
What is Placebo of Nifedipine used for?
Who makes Placebo of Nifedipine?
What drug class is Placebo of Nifedipine in?
What development phase is Placebo of Nifedipine in?
What are the side effects of Placebo of Nifedipine?
What does Placebo of Nifedipine target?
Related
- Drug class: All calcium channel blocker drugs
- Target: All drugs targeting L-type calcium channel
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Compare: Placebo of Nifedipine vs similar drugs
- Pricing: Placebo of Nifedipine cost, discount & access